IE
OCUL icon

Israel Englander’s Ocular Therapeutix OCUL Stock Holding History

Israel Englander’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34,006
Closed -$288K – 6253
2026
Q1 		$288K Sell
34,006
-3,173,875
-99% -$30.2M ﹤0.01% 5023
2025
Q4 		$38.9M Sell
3,207,881
-647,825
-17% -$7.87M 0.02% 987
2025
Q3 		$45.1M Buy
3,855,706
+3,736,560
+3,136% +$44.7M 0.02% 947
2025
Q2 		$1.11M Buy
+119,146
New +$933K ﹤0.01% 4329
2025
Q1 		– Sell
-447,237
Closed -$3.82M – 6247
2024
Q4 		$3.82M Buy
+447,237
New +$4.36M ﹤0.01% 3069
2024
Q2 		– Sell
-169,331
Closed -$1.54M – 6341
2024
Q1 		$1.54M Sell
169,331
-605,836
-78% -$4.3M ﹤0.01% 3953
2023
Q4 		$3.46M Buy
775,167
+89,427
+13% +$264K ﹤0.01% 3117
2023
Q3 		$2.15M Sell
685,740
-1,711,100
-71% -$7M ﹤0.01% 3486
2023
Q2 		$12.4M Buy
2,396,840
+1,360,285
+131% +$8.09M 0.01% 1809
2023
Q1 		$5.46M Buy
1,036,555
+959,233
+1,241% +$4.55M ﹤0.01% 2527
2022
Q4 		$217K Sell
77,322
-123,752
-62% -$410K ﹤0.01% 5285
2022
Q3 		$834K Sell
201,074
-148,127
-42% -$746K ﹤0.01% 4491
2022
Q2 		$1.4M Sell
349,201
-386,532
-53% -$1.46M ﹤0.01% 4051
2022
Q1 		$3.64M Buy
735,733
+443,541
+152% +$2.46M ﹤0.01% 3286
2021
Q4 		$2.04M Buy
292,192
+10,913
+4% +$84.7K ﹤0.01% 3766
2021
Q3 		$2.81M Buy
281,279
+266,135
+1,757% +$2.99M ﹤0.01% 3512
2021
Q2 		$215K Sell
15,144
-179,151
-92% -$2.72M ﹤0.01% 5969
2021
Q1 		$3.19M Buy
+194,295
New +$3.74M ﹤0.01% 3071
2020
Q4 		– Sell
-189,007
Closed -$1.44K – 5477
2020
Q3 		$1.44K Buy
189,007
+165,570
+706% +$1.37M ﹤0.01% 2861
2020
Q2 		$195K Sell
23,437
-992,639
-98% -$6.58M ﹤0.01% 3855
2020
Q1 		$5.03M Buy
1,016,076
+979,183
+2,654% +$4.83M 0.01% 1334
2019
Q4 		$146K Buy
+36,893
New +$128K ﹤0.01% 3944
2019
Q1 		– Sell
-210,273
Closed -$837K – 4227
2018
Q4 		$837K Buy
210,273
+50,118
+31% +$276K ﹤0.01% 2671
2018
Q3 		$1.1M Buy
+160,155
New +$1.01M ﹤0.01% 2819
2018
Q2 		– Sell
-42,369
Closed -$276K – 4061
2018
Q1 		$276K Buy
42,369
+20,192
+91% +$114K ﹤0.01% 3247
2017
Q4 		$99K Buy
22,177
+9,156
+70% +$46.8K ﹤0.01% 3658
2017
Q3 		$80K Buy
+13,021
New +$83.8K ﹤0.01% 3377
2017
Q1 		– Sell
-63,370
Closed -$530K – 3749
2016
Q4 		$530K Buy
+63,370
New +$492K ﹤0.01% 2652
2016
Q3 		– Sell
-28,997
Closed -$144K – 3510
2016
Q2 		$144K Buy
+28,997
New +$287K ﹤0.01% 2967
2016
Q1 		– Sell
-276,978
Closed -$2.6M – 3544
2015
Q4 		$2.6M Buy
+276,978
New +$2.99M 0.01% 1769
2014
Q4 		– Sell
-21,559
Closed -$323K – 4182
2014
Q3 		$323K Buy
+21,559
New +$319K ﹤0.01% 3047

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Israel Englander's OCUL Position: Q2 2026 in Review

Israel Englander sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 34,006 shares — an estimated $288K sold.

Israel Englander first reported a position in OCUL in Q3 2014 and held it in 31 quarters. The position peaked at $45.1M in Q3 2025. 260 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Israel Englander reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 34,006 Ocular Therapeutix shares in Q2 2026, an estimated $288K.
  • Israel Englander first reported a position in Ocular Therapeutix in Q3 2014 and held it in 31 quarters.
  • Israel Englander's Ocular Therapeutix position peaked at $45.1M in Q3 2025.
  • 260 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.